Everything you need to know about BioNTech and the married couple behind the COVID-19 vaccine

Co-founded by Turkish scientists Uğur Şahin and his wife Özlem Türeci, BioNTech is now worth $25 billion

When BioNTech made its stock market debut on Nasdaq last October, the German biotechnology company was valued at just under $3.4 billion.

Just over a year later, BioNTech BNTX, -1.95% is now worth around $25 billion and the Mainz,Germany-based company hit the headlines earlier this week as it became the front-runner in the race to bring a COVID-19 vaccine to market.

Shares in BioNTech soared 14% on Monday after the company said its experimental shot, which is being developed in partnership with U.S. drugmaker Pfizer PFE, -0.87%, was more than 90% effective in preventing COVID-19, based on initial trial results from a Phase 3 clinical trial. This is the first coronavirus vaccine to prove its efficacy in a late-stage clinical study.

Read: BioNTech and Pfizer say their COVID-19 vaccine candidate is 90% effective, a much higher benchmark than anticipated

The stock was 3% up in early trading on Tuesday and has now climbed 219% year-to-date. By comparison, the S&P 500 has risen 9.7% during the same period.

This article was originally posted by MarketWatch.